Embodiments hereof relate to heart valve prostheses and methods for intraluminally deploying heart valve prostheses, and in particular, to heart valve prostheses including coronary access and methods of intraluminally delivering and deploying such heart valve prostheses.
Heart valves, such as the mitral, tricuspid, aortic, and pulmonary valves, are sometimes damaged by disease or by aging, resulting in problems with the proper functioning of the valve. Heart valve problems generally take one of two forms: stenosis in which a valve does not open completely or the opening is too small, resulting in restricted blood flow; or insufficiency in which blood leaks backward across a valve when it should be closed.
Heart valve replacement has become a routine surgical procedure for patients suffering from valve regurgitation or stenotic calcification of the leaflets. Conventionally, the vast majority of valve replacements entail full sternotomy in placing the patient on cardiopulmonary bypass. Traditional open surgery inflicts significant patient trauma and discomfort, requires extensive recuperation times, and may result in life-threatening complications.
To address these concerns, efforts have been made to perform cardiac valve replacements using minimally invasive techniques. In these methods, laparoscopic instruments are employed to make small openings through the patient's ribs to provide access to the heart. While considerable effort has been devoted to such techniques, widespread acceptance has been limited by the clinician's ability to access only certain regions of the heart using laparoscopic instruments.
Still other efforts have been focused upon percutaneous transcatheter (or transluminal) delivery of replacement cardiac valves to solve the problems presented by traditional open surgery and minimally invasive surgical methods. In such methods, a valve prosthesis is compacted for delivery in a catheter and then advanced, for example through an opening in the femoral artery and through the descending aorta to the heart, where the prosthesis is then deployed in the valve annulus (e.g., the aortic valve annulus).
Various types and configurations of prosthetic heart valves are used in percutaneous valve procedures to replace diseased natural human heart valves. The actual shape and configuration of any particular prosthetic heart valve is dependent to some extent upon the valve being replaced (i.e., mitral valve, tricuspid valve, aortic valve, or pulmonary valve). In general, prosthetic heart valve designs attempt to replicate the function of the valve being replaced and thus will include valve leaflet-like structures used with either bioprostheses or mechanical heart valve prostheses. If bioprostheses are selected, the replacement valves may include a valved vein segment or pericardial manufactured tissue valve that is mounted in some manner within an expandable stent frame to make a valved stent. In order to prepare such a valve for percutaneous implantation, one type of valved stent can be initially provided in an expanded or uncrimped condition, then crimped or compressed around a balloon portion of a catheter until it is close to the diameter of the catheter. In other percutaneous implantation systems, the stent frame of the valved stent can be made of a self-expanding material. With these systems, the valved stent is crimped down to a desired size and held in that compressed state within a sheath, for example. Retracting the sheath from this valved stent allows the stent to expand to a larger diameter, such as when the valved stent is in a desired position within a patient.
While some problems of traditional open-heart surgery are overcome by percutaneous transcatheter (transluminal) methods, there are still risks associated with the method including post implantation percutaneous coronary intervention, coronary perfusion, and heart block.
Post implantation coronary access with traditional transcatheter valve implantation (TAVI) may be limited by factors such as implantation height, strut width and cell opening size. Despite technical efforts to optimize valve prostheses placement, these factors may limit future access to coronary arteries and procedures to coronary arteries following transcatheter valve implementation.
Coronary perfusion refers to the pressure gradient between aortic pressure and left ventricle pressure. This gradient drives blood flow into the coronary arteries. Implantation placement, height, cell opening size, partial coronary obstruction, and stent alignment may negatively impact blood flow to the coronary arteries.
Heart block is an abnormal heart rhythm where the heart beats too slowly, called bradycardia. With heart block, the electrical signals that provide normal heart rhythm are either partially or totally blocked between the upper and lower heart. Improper placement of an aortic valve prosthesis is considered a possible contributor to heart block.
There is a need for devices and methods that allow for simultaneous creation of coronary access during transcatheter valve implementation (TAVI) procedures. There is also a need for devices and methods to deploy valve prostheses further from the aortic annulus to minimize heart block in patients undergoing transcatheter valve implantation (TAVI) procedures.
Embodiments hereof are related to an anchor stent assembly to be used with a valve component. The anchor stent assembly has a radially compressed delivery configuration and a radially expanded deployed configuration. The stent assembly includes a generally tubular frame having a first end and a second end, the frame defining a central passage and a central axis. A secondary passage is defined between an inner surface of the frame and an outer surface of an inner rib disposed closer to the central axis than the frame. An extension tube is disposed through the secondary passage. The extension tube includes an extension tube lumen having a first opening at a first end of the extension tube and a second opening at a second end of the extension tube. The anchor stent assembly may include two secondary passages with two extension tubes such that the anchor stent assembly may be deployed in the aorta and the extension tubes may be circumferentially aligned with respective ostia of the left and right coronary arteries.
Embodiments hereof are also directed to a method of implanting a stent assembly at a location in an aorta. The method includes advancing the stent assembly in a radially compressed delivery configuration to the location in the aorta. The stent assembly includes a generally tubular frame having a first end and a second end, a central passage, a central axis, a secondary passage formed between an inner surface of the frame and an outer surface of an inner rib closer to the central axis than the frame, and an extension tube extending through the secondary passage, the extension tube being coupled to the frame and having an extension tube lumen. The method further includes rotationally orienting the stent assembly such that the extension tube is generally circumferentially aligned with an ostium of a coronary artery. The stent assembly is then deployed from the radially compressed delivery configuration to a radially expanded deployed configuration at the location within the aorta. With the stent assembly in place, a coronary stent is advanced in a radially compressed delivery configuration through the extension tube lumen such that a first portion of the coronary stent resides within the extension tube lumen and a second portion of the coronary stent extends into the coronary artery. The coronary stent is then deploying the coronary stent assembly from the radially compressed delivery configuration to a radially expanded deployed configuration. The method may further include delivering a valve component in a radially compressed delivery configuration to a location within a native aortic valve and deploying the valve component such that the valve component expands from the radially compressed delivery configuration to a radially expanded configuration. The valve component may be situated such that a portion of the valve component is disposed within the central passage of the anchor stent assembly when both are deployed.
Embodiments hereof are also directed to an anchor stent assembly for use with a valve component. The anchor stent assembly includes a radially compressed delivery configuration and a radially expanded deployed configuration. The stent assembly includes a generally tubular frame having a proximal end and a distal end and defining a central passage and a central axis. A secondary passage is defined between an inner surface of the frame and an outer surface of an inner rib closer to the central axis than the frame. A proximal alignment arm is coupled to the frame at the proximal end of the frame. A skirt is coupled to the inner rib and the proximal alignment arm such that a coronary channel is defined between an outer surface of the skirt and the frame. In an embodiment, the secondary passage comprises two secondary passages, and the stent assembly is configured to be rotationally oriented such that one of the secondary passages is circumferentially aligned with an ostium of the left coronary artery and the other of the secondary passages is circumferentially aligned with an ostium of the right coronary artery. The portion of the skirt attached to the proximal alignment arm defines a coronary pocket between the outer surface of the skirt and the aortic sinus in which the proximal alignment arm is disposed.
Embodiments hereof are also directed to a method of implanting an anchor stent assembly at a location within an aorta. The anchor stent assembly includes a frame with a central passage and a central axis, a secondary passage formed between an inner surface of the frame and an outer surface of an inner rib closer to the central passage, a proximal alignment arm extending proximally from a proximal end of the frame, and a skirt coupled to the inner rib and the proximal alignment arm. The anchor stent assembly is advanced in a radially compressed delivery configuration to the location in the aorta. The method includes rotationally orienting the anchor stent assembly such that the secondary passage is generally circumferentially aligned with an ostium of a coronary artery. The method further includes deploying the anchor stent assembly from the radially compressed delivery configuration to a radially expanded deployed configuration at the location within the aorta such that the proximal alignment arm extends into an aortic sinus below the ostium of the coronary artery and a coronary channel is formed between an outer surface of the skirt at the inner rib and an inner surface of aorta, and a coronary pocket is formed between the outer surface of the skirt at the proximal alignment arm and an inner surface of the aortic sinus. The method may further include delivering a valve component in a radially compressed delivery configuration to a location within a native aortic valve, and deploying the valve component such that the valve component expands from the radially compressed delivery configuration to a radially expanded deployed configuration.
Embodiments hereof are also directed to a valve assembly including a generally tubular frame, a prosthetic valve coupled to the frame, a coronary orifice extending between an inner surface and an outer surface of the frame, and a coronary arm having a first end coupled to the coronary orifice. The coronary arm has a generally tubular structure and defines a longitudinal passage with a longitudinal axis. The coronary arm includes a longitudinally collapsed delivery configuration wherein a second end of the coronary arm is adjacent the first end, and a longitudinally extended deployed configuration wherein the second end is spaced from the first end. The prosthetic valve may include two coronary arms and is configured to be deployed at a native aortic valve such that one of the coronary arms extends into the left coronary artery and the other coronary arm extends into the right coronary artery.
Embodiments hereof are also directed to a method of implanting a valve assembly at a location of a native valve. The valve assembly includes a generally tubular frame defining a central passage and a central axis. A prosthetic valve is coupled to the frame. A coronary orifice extends between an inner surface and an outer surface of the frame. A coronary arm includes a first end coupled to the coronary orifice of the frame. A second end of the coronary arm is disposed adjacent to the first end with the coronary arm in a longitudinally collapsed delivery configuration. The method includes advancing the valve assembly in a radially compressed delivery configuration with the coronary arm in the longitudinally collapsed configuration to the location of the native valve. The valve assembly is rotationally oriented such that the coronary arm is aligned with an ostium of a coronary artery. The valve assembly is deployed such that the frame expands from the radially compressed delivery configuration to a radially expanded deployed configuration with the frame engaging an inner surface of the native valve and the aortic sinuses. The coronary arm is from the longitudinally compressed delivery configuration to a longitudinally extended deployed configuration such that the second end of the coronary arm is extended away from the first end and the second end is disposed within the coronary artery. The valve assembly may include two coronary arms, and the method includes rotationally orienting the valve assembly such that one of the two coronary arms is aligned with the left coronary artery and the other of the two coronary arms is aligned with the right coronary artery.
The foregoing and other features and advantages of the invention will be apparent from the following description of embodiments hereof as illustrated in the accompanying drawings. The accompanying drawings, which are incorporated herein and form a part of the specification, further serve to explain the principles of the invention and to enable a person skilled in the pertinent art to make and use the invention. The drawings are not to scale.
Specific embodiments of the present invention are now described with reference to the figures, wherein like reference numbers indicate identical or functionally similar elements. The terms “distal” and “proximal” when used in the following description to refer to a catheter or delivery system are with respect to a position or direction relative to the treating clinician. Thus, “distal” and “distally” refer to positions distant from or in a direction away from the clinician and “proximal” and “proximally” refer to positions near or in a direction toward the clinician. When the terms “distal” and “proximal” are used in the following description to refer to a device to be implanted into a vessel, such as an anchor stent assembly or valve component, they are used with reference to the direction of blood flow from the heart. Thus, “distal” and “distally” refer to positions in a downstream direction with respect to the direction of blood flow and “proximal” and “proximally” refer to positions in an upstream direction with respect to the direction of blood flow.
Frame 102 in the exemplary embodiment includes an outflow section 106, an inflow section 110, and a constriction region 108 between the inflow and outflow sections. Frame 102 may comprise a plurality of cells having sizes that vary along the length of the prosthesis. When configured as a replacement for an aortic valve, inflow section 110 extends into and anchors within the aortic annulus of a patient's left ventricle and outflow section 106 is positioned in the patient's ascending aorta. Frame 102 also may include eyelets 130 for use in loading the heart valve prosthesis 100 into a delivery catheter.
Valve body 104 may include a skirt 121 affixed to frame 102, and leaflets 112, 114, 116. Leaflets 112, 114, 116 may be attached along their bases to skirt 121, for example, using sutures or a suitable biocompatible adhesive. Adjoining pairs of leaflets are attached to one another at their lateral ends to form commissures 124, 126, 128, with free edges 118, 120, 122 of the leaflets forming coaptation edges that meet in an area of coaptation, as described in the '765publication and shown in
The following detailed description is merely exemplary in nature and is not intended to limit the invention or the application and uses of the invention. Although the description of the invention is in the context of transcatheter aortic valve implantation, the invention may also be used in any other body passageways where it is deemed useful. Furthermore, there is no intention to be bound by any expressed or implied theory presented in the preceding technical field, background, brief summary or the following detailed description.
Anchor stent 202 includes a frame 206 having a first or proximal end 212, and a second or distal end 210, as shown in
Frame 206 is constructed of a series of vertical struts or stringers 220 arranged parallel to a central longitudinal axis LA1 of frame 206. Stringers 220 are spaced radially from the central longitudinal axis LA1 and are spaced circumferentially from each other around a circumference of the frame 206. Stringers 220 are connected by a series of radially collapsible outer struts or ribs 224 that run circumferentially between adjacent stringers 220. The outer surfaces of outer ribs 224 and the outer surfaces of stringer 220 form the outer surface of frame 206. While the embodiment of
A first extension tube channel or secondary passage 221a is formed between adjacent stringers 220a and 220b and between outer ribs 224 and corresponding inner ribs 222 disposed between stringers 220a and 220b. Inner ribs 222 are disposed closer to central longitudinal axis LA1 than outer ribs 224 such that first extension tube channel 221a is formed between outer ribs 224 and inner ribs 222 and first extension tube channel 221a extends longitudinally from first end 212 to second end 210 of frame 206. Similarly, a second extension tube channel or secondary passage 221b is formed between adjacent stringers 220c and 220d and between outer ribs 224 and corresponding inner ribs 222 disposed between stringers 220c and 220d. Inner ribs 222 are disposed closer to central longitudinal axis LA1 than outer ribs 224 such that second extension tube channel 221b is formed between outer ribs 224 and inner ribs 222 and second extension tube channel 221b extends from first end 212 to second end 210 of frame 206. First and second extension tube channels 221a/221b are spaced apart from each other around the circumference of frame 206 such that they generally align with circumferentially with a corresponding coronary artery when deployed adjacent the aortic sinuses of an aortic valve. Thus, first and second extension tube channels 221a/221b are generally spaced circumferentially approximately 120 degrees apart.
Stringers 220, outer ribs 224 and inner ribs 222 are collapsible structures and may be constructed of materials such as, but not limited to, stainless steel, Nitinol, or other suitable materials for the purposes disclosed herein. Outer ribs 224 and inner ribs 222 may be connected to stringers 220 by methods such as, but not limited to fusing, welding, or other methods suitable for the purposes disclosed herein. Alternatively, frame 206, including stringers 220, outer ribs 224, and inner ribs 222 may be formed by cutting a pattern from a tube, such as by laser-cutting, chemical etching, or other suitable methods. In other embodiments, the pattern may be cut from a flat sheet of material and then rolled to form frame 206. Although frame 206 has been described with stringers 220, outer ribs 224, and inner ribs 222, other structures may be used to form frame 206, such as, but not limited to, rings formed from sinusoidally shaped struts, struts forming cells (such as diamond shaped or hexagonally shaped cells), and other structures. The details of such structures are not essential provided that the frame includes a central passage and at least one secondary passage as described herein.
Extension tubes 270 are disposed within respective extension tube channels 221a/221b of frame 206. In the embodiment shown, extension tubes 270 extend from first end 212 to second end 210 of frame 206. However, in other embodiments, extension tubes need not extend the entire length of frame 206. Extension tubes 270 include a first end 272 adjacent first end 212 of frame 206, and a second end 274 adjacent second end 210 of anchor frame 206. First end 272 of extension tube 270 may be flared as shown such that the diameter of first end 272 is greater than the diameter of second end 274. Each extension tube 270 forms a respective extension tube lumen 276. Extension tube 270 is constructed of materials such as, but not limited to woven polyester, Dacron mesh, and PTFE (woven, mesh, or elecrospun), or other materials suitable for the purposes disclosed herein. Extension tube 270 may be connected to anchor frame 206 at inner rib contact point 226 and outer rib contact point 227 and may be attached by methods such as, but not limited to sutures, adhesives, fusing, welding, or other methods suitable for the purposes disclosed herein.
Although the embodiment of
Another embodiment of an anchor stent assembly 300 is shown in
Anchor stent 302 includes a frame 306 having a first or proximal end 312, and a second or distal end 310, as shown in
Frame 306 is constructed of a series of vertical struts or stringers 320360 arranged parallel to a central longitudinal axis LA2 of frame 306. Stringers 320 are spaced radially from the central longitudinal axis LA2 and are spaced circumferentially from each other around the circumference of frame 306. Stringers 320 are connected by a series of radially collapsible outer struts or ribs 324 that run circumferentially between adjacent stringers 320. The outer surfaces of outer ribs 324 and the outer surfaces of stringers 320 for the outer surface of frame 306. While the embodiment of
A first extension channel or secondary passage 321a is formed between adjacent stringers 320a and 320b and between outer ribs 324 and corresponding inner ribs 322 disposed between stringers 320a and 320b. Inner ribs 322 are disposed closer to central longitudinal axis LA2 than outer ribs 324 such that first extension channel 321a is formed between outer ribs 324 and inner ribs 322 and first extension channel 321a extends longitudinally from first end 310 to second end 312. Similarly, a second extension channel or secondary passage 321b is formed between adjacent stringers 320c and 320d and between outer ribs 324 and corresponding inner ribs 322 disposed between stringers 320c and 320d. Inner ribs 322 are disposed closer to central longitudinal axis LA1 than outer ribs 324 such that second extension channel 321b is formed between outer ribs 324 and inner ribs 322 and second extension channel 321b extends from first end 312 to second end 310 of frame 306. First and second extension channels 321a/321b are spaced apart from each other around the circumference of frame 306 such that they generally align circumferentially with a corresponding coronary artery when deployed adjacent the aortic sinuses of an aortic valve. Thus, first and second channels 321a/321b are generally spaced circumferentially approximately 120 degrees apart.
As described above, frame 306 is generally similar to frame 206 of
Anchor stent 302 further includes proximal alignment arms 362, 364, and 366 extending proximally from first end 312 of frame 306. In the embodiment shown in
Anchor stent assembly 300 further includes a skirt 380 attached to an inside surface thereof to separate central passage 308 from extension channels 321a and 321b, as shown in
With anchor stent assembly deployed with frame 306 in the aorta and proximal alignment arms 362, 364, 366 disposed within the aortic sinuses, skirt 380 is configured such that the wall of the aortic sinuses and skirt 380 attached to frame 306 and inner ribs 322 enclose extension channels 321 such that each extension channel 321 and corresponding coronary pocket 382 forms a coronary channel 376 for direct path for blood flow to the left or right coronary ostia.
An embodiment of a method of delivering and deploying an anchor stent assembly and a corresponding valve component is schematically represented in
In the method, a guidewire 502 is advanced distally, i.e., away from the clinician, through the aorta 400, past the sinotubular junction 414, and into the aortic sinuses 412 in the region of the aortic valve 416 and annulus 418, as shown in
Once delivery system 500 has been advanced to the desired location, such as when first end 212 of anchor stent 202 is generally aligned with sinotubular junction 414, and extension tubes 270 rotationally aligned with coronary ostia 422, outer sheath 504 is retracted proximally, i.e., towards the clinician, as shown in
Outer sheath 504 is further retracted proximally, i.e., towards the clinician, to complete deployment of anchor stent assembly 200 from outer sheath 504. In other words, sheath 504 is retracted such that anchor stent assembly 200 is no longer constrained by sheath 504.
With anchor stent assembly 200 fully deployed, delivery system 500 may be retracted proximally, i.e., towards the clinician, and removed in a manner consistent with current procedures known to those in the art. Anchor stent assembly 200 remains in the fully deployed configuration with extension tubes 270 generally rotationally aligned with, but not obstructing coronary ostia 422, as shown in
A steerable catheter 530 is advanced distally, i.e., away from the clinician and into one of extension tubes 270, as shown in
Once in place within extension tube 270 and coronary artery 420, a guidewire 502 is extended through catheter 530. With guidewire 502 positioned through extension tube 270 and into coronary artery 420, steerable catheter 530 is retracted proximally, i.e., toward the clinician, and removed in a manner consistent with current procedures known to those in the art. Guidewire 502 remains disposed through extension tube 270 and into coronary artery 420, as shown in
A coronary stent delivery system 550 for delivering a coronary stent 552 is advanced distally, i.e., away from the clinician, over guidewire 502 to a location in the coronary artery 420 via coronary ostium 422, as shown in
Once delivery system 550 has been advanced to the desired location, the balloon is inflated, causing coronary stent 552 to expand radially outward, engaging the inner wall of extension tube 270 and inner wall of coronary artery 420, as shown in
Valve component 240 may now be delivered and deployed at the native aortic valve 416 using methods and procedures known in the art. As shown in
Similar to the description above, guidewire 502 is advanced distally, i.e., away from the clinician, through the aorta 400, past the sinotubular junction 414, and into the aortic sinuses 412 in the region of the aortic valve 416 and annulus 418, as shown in
A delivery system 500 for delivering anchor stent assembly 300 being advanced distally, i.e., away from the clinician, over guidewire 502 to a location in the aortic sinuses 412, as shown in
Once delivery system 500 has been advanced to the desired location, such as when first end 312 of frame 306 of anchor stent 302 is generally aligned with sinotubular junction 414, and proximal alignment arms 364 and 366 are rotationally aligned with and encircle, but do not obstruct, coronary ostia 422, outer sheath 504 is retracted proximally, i.e., towards the clinician, as shown in
Outer sheath 504 is further retracted proximally, i.e., towards the clinician, to complete deployment of anchor stent assembly 300 from outer sheath 504. In other words, sheath 504 is retracted such that anchor stent assembly 300 is no longer constrained by sheath 504.
With anchor stent assembly 300 fully deployed, delivery system 500 may be retracted proximally, i.e., towards the clinician, and removed in a manner consistent with procedures known to those in the art. Anchor stent assembly 300 remains in the fully deployed configuration such that extension channels 321a/321b are generally rotationally aligned with respective coronary ostia 422 and proximal arms 364 and 366 encircle, but do not obstruct coronary ostia 422, as shown in
Valve component 240, as described above, may now be delivered and deployed at the native aortic valve 416 using methods and procedures known in the art. Once in place, prosthetic valve 350 resides within valve frame 342 at annulus 418 as shown in
Frame 606 includes a first end 612 and a second end 610, as shown in
Each coronary arm 650 is a generally tubular structure, defining a longitudinal passage 658 with a longitudinal axis LA4. Longitudinal axis LA4 is generally transverse to longitudinal axis LA3. Although longitudinal axis LA4 has been defined with respect to one of the coronary arms 650, those skilled in the art would recognize that the coronary arms do not need to align with each other. Instead, coronary arms 650 extend from frame 606 at locations such that coronary arms 650 can extend into a respective coronary artery, as described in more detail below. Thus, coronary arms 650 may be longitudinally offset, if appropriate. Coronary arms 650 may include struts 651 coupled to graft material 652, similar to a stent-graft construction. Struts 651 may be any suitable material generally used in stent, such as, but not limited to, stainless steel or Nitinol. Struts 651 may be the same material as frame 606. Graft material 652 may be any suitable material generally used for a graft such as, but not limited to, woven polyester such as polyethylene terephthalate, polytetrafluoroethylene (PTFE), other polymers, or other biocompatible materials. Graft material 652 and struts 651 may be coupled by sutures, fusion, or other coupling methods known in the art. Further, graft material 652 may be coupled to the outer surface or inner surface of struts 651. Coronary arms 650 may be coupled to frame 606 by fusion, laser or ultrasonic welding, mechanical connections such as sutures, or other methods suitable for the purposes disclosed herein. In another embodiment, struts 651 of coronary arms 650 may be constructed integrally with frame 606.
Coronary arms 650 have a first end 656 and a second end 654, and a longitudinally collapsed delivery configuration and a longitudinally extended deployed configuration. When in the longitudinally collapsed delivery configuration, second end 654 is adjacent to first end 656, as shown in
Coronary arms 650 are configured such that the longitudinal axis of each coronary arm 650 generally aligns with a corresponding longitudinal axis of the coronary artery into which it is to be inserted.
While the embodiment of
Prosthetic valve 620 may be any prosthetic valve. For example, and not by way of limitation, prosthetic valve 620 may be similar to valve body 104 described above with respect to
A method of delivering and deploying valve assembly 600 in accordance with an embodiment hereof is schematically represented in
A delivery system 700 for delivering valve assembly 600 is advanced distally, i.e., away from the clinician, over guidewire 702 to a location at the annulus 418 of the heart, as shown in
Once delivery system 700 has been advanced to the desired location such that each coronary arm 650 is generally rotationally and longitudinally aligned with the corresponding coronary ostium 422 of the corresponding coronary artery 420, outer sheath 704 is retracted proximally, i.e., towards the clinician, to deploy frame 606 of valve assembly 600, as shown in
Outer sheath 704 is further retracted proximally, i.e., towards the clinician, to complete deployment of valve assembly 600 from outer sheath 704. Sheath 704 is retracted such that valve assembly 600 is no longer constrained by sheath 704 and expands radially outward, as shown in
With valve assembly 600 fully deployed, delivery system 700 may be retracted proximally, i.e., towards the clinician, and removed in a manner consistent with procedures known to those in the art. Valve assembly 600 remains in the fully deployed configuration with coronary arms 650 in the longitudinally collapsed delivery configuration and aligned of the corresponding coronary arteries 420, as shown in
A steerable catheter or pushrod 730 is advanced distally, i.e., away from the clinician and into one coronary arms 650, as shown in
Once in place within telescoping coronary arm 650, pushrod 730 is advanced distally i.e., away from the clinician, such that distal end 732 of pushrod 730 engages second end 654 of coronary arm 650 and pushes second end 654 of coronary arm 650. Pushrod 730 continues to be advanced to extend second end 654 of coronary arm 650 into coronary artery 420, thereby deploying coronary arm 650 from its longitudinally collapsed delivery configuration to its longitudinally extended deployed configuration, as shown in
Once coronary arm 650 is in its longitudinally extended deployed configuration with second end 654 of coronary arm 650 disposed within coronary artery 420, steerable catheter 730 is retracted proximally, i.e., toward the clinician, and removed in a manner consistent with procedures known to those in the art. The procedure is repeated for the other coronary arm 650.
In another embodiment, coronary arms 650 may be formed of shape memory material such that they are self-extending. Accordingly, the pre-formed shape of each coronary arm 650 is the longitudinally extended deployed configuration. The coronary arms 650 are collapsed to the longitudinally collapsed delivery configuration when loaded into outer sheath 704. When outer sheath 704 is retracted, as described above, coronary arms 650 return to their pre-formed, longitudinally extended configuration without the use of the pushrod 730 described above.
Valve assembly 600 is shown in a fully deployed configuration shown in
While various embodiments according to the present invention have been described above, it should be understood that they have been presented by way of illustration and example only, and not limitation. It will be apparent to persons skilled in the relevant art that various changes in form and detail can be made therein without departing from the spirit and scope of the invention. Thus, the breadth and scope of the present invention should not be limited by any of the above-described exemplary embodiments, but should be defined only in accordance with the appended claims and their equivalents. It will also be understood that each feature of each embodiment discussed herein, and of each reference cited herein, can be used in combination with the features of any other embodiment
This application is a divisional of U.S. patent application Ser. No. 14/841,749, filed Sep. 1, 2015, the contents of which are incorporated by reference herein in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
3574865 | Hamaker | Apr 1971 | A |
3671979 | Moulopoulos | Jun 1972 | A |
3997923 | Possis | Dec 1976 | A |
4056854 | Boretos et al. | Nov 1977 | A |
RE31040 | Possis | Sep 1982 | E |
4506394 | Bedard | Mar 1985 | A |
4705516 | Barone et al. | Nov 1987 | A |
4790843 | Carpentier et al. | Dec 1988 | A |
4994077 | Dobben | Feb 1991 | A |
5032128 | Alonso | Jul 1991 | A |
5332402 | Teitelbaum | Jul 1994 | A |
5370685 | Stevens et al. | Dec 1994 | A |
5397351 | Pavcnik et al. | Mar 1995 | A |
5554185 | Block et al. | Sep 1996 | A |
5716370 | Williamson, IV et al. | Feb 1998 | A |
5855601 | Bessler et al. | Jan 1999 | A |
5984959 | Robertson et al. | Nov 1999 | A |
6074418 | Buchanan et al. | Jun 2000 | A |
6106550 | Magovern | Aug 2000 | A |
6129756 | Kugler | Oct 2000 | A |
6168614 | Andersen et al. | Jan 2001 | B1 |
6176877 | Buchanan et al. | Jan 2001 | B1 |
6217611 | Klostermeyer | Apr 2001 | B1 |
6419696 | Ortiz et al. | Jul 2002 | B1 |
6425916 | Garrison et al. | Jul 2002 | B1 |
6468305 | Otte | Oct 2002 | B1 |
6569196 | Vesely | May 2003 | B1 |
6645242 | Quinn | Nov 2003 | B1 |
6730121 | Ortiz et al. | May 2004 | B2 |
6764508 | Roehe et al. | Jul 2004 | B1 |
6786925 | Schoon et al. | Sep 2004 | B1 |
6790229 | Berreklouw | Sep 2004 | B1 |
6846325 | Liddicoat | Jan 2005 | B2 |
6893459 | Macoviak | May 2005 | B1 |
6908481 | Cribier | Jun 2005 | B2 |
6939365 | Fogarty et al. | Sep 2005 | B1 |
6964684 | Ortiz et al. | Nov 2005 | B2 |
7097659 | Woolfson et al. | Aug 2006 | B2 |
7147663 | Berg et al. | Dec 2006 | B1 |
7172625 | Shu et al. | Feb 2007 | B2 |
7186265 | Sharkawy et al. | Mar 2007 | B2 |
7291168 | Macoviak et al. | Nov 2007 | B2 |
7300463 | Liddicoat | Nov 2007 | B2 |
7311730 | Gabbay | Dec 2007 | B2 |
7381220 | Macoviak et al. | Jun 2008 | B2 |
7503930 | Sharkawy et al. | Mar 2009 | B2 |
7513909 | Lane et al. | Apr 2009 | B2 |
7527646 | Rahdert et al. | May 2009 | B2 |
7578843 | Shu | Aug 2009 | B2 |
7597711 | Drews et al. | Oct 2009 | B2 |
7611535 | Woolfson et al. | Nov 2009 | B2 |
7648528 | Styre | Jan 2010 | B2 |
7691144 | Chang et al. | Apr 2010 | B2 |
7708775 | Rowe et al. | May 2010 | B2 |
7717955 | Lane et al. | May 2010 | B2 |
7722667 | Buchanan | May 2010 | B1 |
7758640 | Vesely | Jul 2010 | B2 |
7771469 | Liddicoat | Aug 2010 | B2 |
7871436 | Ryan et al. | Jan 2011 | B2 |
7887583 | Macoviak | Feb 2011 | B2 |
7951197 | Lane et al. | May 2011 | B2 |
7959674 | Shu et al. | Jun 2011 | B2 |
7981153 | Fogarty et al. | Jul 2011 | B2 |
8025695 | Fogarty et al. | Sep 2011 | B2 |
8083793 | Lane et al. | Dec 2011 | B2 |
8105377 | Liddicoat | Jan 2012 | B2 |
8163013 | Machold et al. | Apr 2012 | B2 |
8187207 | Machold et al. | May 2012 | B2 |
8287591 | Keidar et al. | Oct 2012 | B2 |
9393140 | Argentine et al. | Jul 2016 | B2 |
20040034411 | Quijano et al. | Feb 2004 | A1 |
20050137686 | Salahieh et al. | Jun 2005 | A1 |
20060287717 | Rowe et al. | Dec 2006 | A1 |
20080082166 | Styrc et al. | Apr 2008 | A1 |
20080208327 | Rowe | Aug 2008 | A1 |
20080275540 | Wen | Nov 2008 | A1 |
20080275548 | Svensson | Nov 2008 | A1 |
20090240320 | Tuval et al. | Sep 2009 | A1 |
20090287145 | Cragg et al. | Nov 2009 | A1 |
20100076548 | Konno | Mar 2010 | A1 |
20100161036 | Pintor et al. | Jun 2010 | A1 |
20100179649 | Richter et al. | Jul 2010 | A1 |
20100249915 | Zhang | Sep 2010 | A1 |
20100312333 | Navia et al. | Dec 2010 | A1 |
20110118822 | Welch | May 2011 | A1 |
20110172765 | Nguyen et al. | Jul 2011 | A1 |
20130144373 | Shahriari | Mar 2013 | A1 |
20130103134 | Minion | Apr 2013 | A1 |
20140316513 | Tang | Oct 2014 | A1 |
20140330367 | Thapliyal | Nov 2014 | A1 |
20150105850 | Shahriari | Apr 2015 | A1 |
20150257881 | Bortlein | Sep 2015 | A1 |
20160081787 | Parodi | Mar 2016 | A1 |
20160081829 | Rowe | Mar 2016 | A1 |
Number | Date | Country |
---|---|---|
202207217 | May 2012 | CN |
203029425 | Jul 2013 | CN |
2522306 | Nov 2012 | EP |
2906454 | Apr 2008 | FR |
WO2000047139 | Aug 2000 | WO |
WO2007002423 | Jan 2007 | WO |
WO2007081820 | Jul 2007 | WO |
WO2007130537 | Nov 2007 | WO |
WO2007149933 | Dec 2007 | WO |
WO2008101193 | Aug 2008 | WO |
WO2014197743 | Dec 2014 | WO |
Entry |
---|
PCT/US2014/058913, PCT International Search Report and the Written Opinion, dated Dec. 23, 2014. |
Bonhoeffer P., et al., “Percutaneous Insertion of the Pulmonary Valve”, Pediatric Cardiology, 2002; 39:1664-1669. |
Anderson H R, et al., “Transluminal Implantation of Artificial Heart Valves”, EUR Heart J., 1992; 13:704-708. |
Anderson, H. R., et al., “Transluminal Catheter Implantation of New Expandable Artificial Cardiac Valve (the stent-valve) in the Aorta and the Beating Heart of Closed Chest Pigs”, EUR Heart J.[Abstract], 1990;11 (Suppl):224a. |
Hilbert S. L., “Evaluation of Explanted Polyurethane Tri Leaflet Cardiac Valve Prosthesis”, J Thorac Cardiovascular Surgery, 1989; 94:419-29. |
Block P C, “Clinical and Hemodynamic Follow-Up After Percutaneous Aortic Valvuloplasty in the Elderly”, The American Journal of Cardiology, vol. 62, Oct. 1, 1998. |
Boudjemline, Y., “Steps Toward Percutaneous Aortic Valve Replacement”, Circulation, 2002; 105:775-558. |
Bonhoeffer, P., “Transcatheter Implantation of a Bovine Valve in Pulmonary Position, a Lamb Study”, Circulation, 2000: 102:813-816. |
Boudjemline, Y., “Percutaneous Implantation of a Valve in the Descending Aorta in Lambs”, EUR Heart J, 2002; 23:1045-1049. |
Kulkinski, D., “Future Horizons in Surgical Aortic Valve Replacement: Lessons Learned During the Early Stages of Developing a Transluminal Implantation Technique”, ASAIO J, 2004; 50:364-68. |
PCT/US2016/049503, Communication Relating to the Results of the Partial International Search, dated Oct. 21, 2015. |
PCT/US2016/049503, The International Search Report and the Written Opinion of the International Searching Authority, dated Jan. 13, 2017. |
Chinese Office Action, CN Appln No. 201680049998.1, 11 pages dated Jul. 13, 2020. |
Number | Date | Country | |
---|---|---|---|
20190209353 A1 | Jul 2019 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14841749 | Sep 2015 | US |
Child | 16358072 | US |